ClinicalTrials.gg
CompletedNCT02247518CKD-397DDI(A)Updated Aug 20, 2015

CKD-397 Drug-drug Interaction Study (A)

A Phase 1 interventional study of Cialis Tab. 5mg and Harnal-D Cap. 0.2mg in Healthy, sponsored by Chong Kun Dang Pharmaceutical. Completed at 1 site in Korea, Republic of. Open to male participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-08-20.

Sponsored by Chong Kun Dang Pharmaceutical · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
19 Years to 55 Years
Sex
Male
01

Study summary

The purpose of this study is to investigate to effect of tamsulosin on the pharmacokinetic properties of tadalafil

Read the detailed description

This study is a randomized, open-label, mutiple dosing, 2-way crossover design to evaluate the pharmacokinetic effect of tamsulosin(0.2mg) on tadalafil(5mg) in healthy male subjects. Subjects will receive repeated dose of tadalafil (5mg*1t/day) or tadalafil (5mg*1t/day) / tamsulosin (0.2mg*1t/day) for 5days. Each treatment period was separated by a washout period of at least 10 days.

Each period of study will enroll 8 healthy male subjects. Blood samples for pharmacokinetic analysis will be taken at regular intervals after dosing. Safety will be assessed by measurement of blood pressure, heart rate, safety laboratory data, and review of adverse events.

02

Conditions studied

  • Healthy

Keywords

  • Male
  • Volunteers
03

In context

Lead sponsor

Chong Kun Dang Pharmaceutical is the lead sponsor of 299 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy man age 19 years or more and less than 55 years old at the time of screening.
  • more than 17.5kg / m2 and less than 30.5kg / m2 and weight more than 55kg
  • Subject without congenital or chronic diseases and no psychotic symptoms or findings from the medical examination.
  • Suitable subject who is determined by laboratory tests such as hematology tests, blood chemistry, urinalysis test according to the characteristics of the drug and screening tests such as test.
  • Subject who fully understand the clinical trials after in-depth explanation given prior to the clinical study, decided to join the clinical trials by their will and signed consent form which approved by Chonbuk National University Hospital IRB.
  • Subjects who are able to comply with all scheduled visits, laboratory tests and other procedures.

Exclusion criteria

Exclusion Criteria:

  • Subject who has a history of blood, kidneys, endocrine, respiratory, gastrointestinal, urinary, cardiovascular, hepatic, psychiatric, neurological or allergic diseases that is (Except untreated asymptomatic seasonal allergies at the time of administration)
  • Subject who has a history of gastrointestinal disease or gastrointestinal surgery which can affect drug absorption.
  • Showing the value that corresponds to following laboratory parameters: or AST > 2* .
  • Alcohol > 210g/week, within 6 months prior to the screening.
  • Taking the medication involved in other clinical trials within two months before the first dose medication characters.
  • Sitting Systolic Blood Pressure ≥ 140 mmHg, Diastolic Blood Pressure ≥ 90 mmHg at the time of screening.
  • History of alcohol or drug abuse, within 1 year
  • Positive result in urine drug test(Amphetamines, Cocaine, Opioid, Benzodiazepines, Cannabinoid)
  • Positive result in Serology test(, , (Human Immunodeficiency Virus), TPPA(qual)).
  • Subject who takes an abnormal meal which can affect the ADME of drug.
  • Subjects who treated with metabolizing enzyme inducers or inhibitors such as barbitals within 30days prior to the first dosing.
  • Smoker (> 20cigarettes/day)
  • Subjects who takes ETC or OTC medicine within 10days before the first IP administration.
  • Subject who done the whole blood donation within two months or component blood donation within 1 month prior to the first dosing.
  • Subject who can increase risk due to clinical test and administration of drugs or has Severe grade / chronic medical, mental condition or abnormal laboratory result that may interfere with the analysis of test results.
  • Subject with taking any forms of organic nitrate periodically and/or intermittently.
  • Subject with known hereditary degenerative retinal disease including retinitis pigmentosa.
  • Subject with serious history of or allergy to product.
  • Subject who Lost sight of one eye by Non-arteritic anterior ischemic optic neuropathy (NAION).
  • Subject with genetic problems such as galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption.
  • Orthostatic hypotension
  • Subjects who is not able to comply with guidelines described in the protocol.
  • Subjects who is determined by investigator's decision as unsuitable for clinical trial participation.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Other
    Group1: Treatment A + Treatment B, PO

    Treatment A : Tadarafil 5mg\*1t/day for 5days, Treatment B : Tadarafil 5mg\*1t/day and Tamsulosin 0.2mg\*1t/day for 5days, Each treatment period was separated by a washout period of at least 10 days.

    Drug: Cialis Tab. 5mg · Drug: Harnal-D Cap. 0.2mg

  • Other
    Group2: Treatment B + Treatment A, PO

    Treatment A : Tamsulosin 0.2mg\*1t for 5days, Treatment B : Tamsulosin 0.2mg\*1t/day and Tadalafil 5mg\*1t/day for 5days, Each treatment period was separated by a washout period of at least 10 days.

    Drug: Cialis Tab. 5mg · Drug: Harnal-D Cap. 0.2mg

Interventions

06

What researchers measure

Primary outcomes

  1. Tadalafil 5mg AUCt(0-24)

    Time frame: 1D 0h, 3D 0h, 4D 0h, 5D 0h, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 5h, 6h, 8h, 12h, 24h

  2. Tadalafil 5mg Cmax

    Time frame: 1D 0h, 3D 0h, 4D 0h, 5D 0h, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 5h, 6h, 8h, 12h, 24h

Secondary outcomes

  1. Tadalafil Css,min

    Time frame: 1D 0h, 3D 0h, 4D 0h, 5D 0h, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 5h, 6h, 8h, 12h, 24h

  2. Tadalafil Css,av

    Time frame: 1D 0h, 3D 0h, 4D 0h, 5D 0h, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 5h, 6h, 8h, 12h, 24h

  3. Tadalafil Tss,max

    Time frame: 1D 0h, 3D 0h, 4D 0h, 5D 0h, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 5h, 6h, 8h, 12h, 24h

  4. Tadalafil t1/2

    Time frame: 1D 0h, 3D 0h, 4D 0h, 5D 0h, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 5h, 6h, 8h, 12h, 24h

  5. Tadalafil CL/F

    Time frame: 1D 0h, 3D 0h, 4D 0h, 5D 0h, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 5h, 6h, 8h, 12h, 24h

  6. Tadalafil Vd/F

    Time frame: 1D 0h, 3D 0h, 4D 0h, 5D 0h, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 5h, 6h, 8h, 12h, 24h

  7. Tadalafil fluctuation[(Css,max-Css,min)/Css,av]

    Time frame: 1D 0h, 3D 0h, 4D 0h, 5D 0h, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 5h, 6h, 8h, 12h, 24h

  8. Tadalafil swing[(Css,max-Css,min)/Css,min]

    Time frame: 1D 0h, 3D 0h, 4D 0h, 5D 0h, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 5h, 6h, 8h, 12h, 24h

07

Study locations

1 site
  • Chonbuk National University Hospital
    Jeonju-si, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2014, a primary completion of Oct 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2014
First posted
Sep 25, 2014
Start
Sep 2014
Primary completionActual
Oct 2014
CompletionActual
Dec 2014
Last update
Aug 20, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02247518
Responsible party
Sponsor
First posted
Sep 25, 2014
Start date
Sep 2014
Primary completion
Oct 2014
Completion
Dec 2014
Last update
Aug 20, 2015

Study contacts

Min Gul Kim, PhD
principal investigator · Chonbuk National University Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tadalafil · Tamsulosin

Start the discussion